Laura Joszt

The shift toward fibrosis end points and noninvasive biomarkers in MASH trials may ease enrollment, improve assessment, and reduce biopsy use, Zobair M. Younossi, MD, said.

A new international platform trial groups rare pediatric sarcoma substudies under 1 protocol to speed drug access and data collection.

New hypertension drugs cost over $800,000 per QALY vs generics, well above cost-effectiveness limits, ICER's draft report finds.

A gene tied to poor sarcoma prognosis also rose fastest in pazopanib-sensitive sarcoma cell lines, a new exploratory study suggests.

Diet, alcohol, and physical activity offer actionable targets for clinicians managing MASLD, according to Zobair M. Younossi, MD.

Arshad Khanani, MD, weighs Wnt- and Tie2-targeting agents against gene therapy and makes the case for payers to look past price to long-term value.

Hepatitis B re-engagement efforts are underreported in lower-resource settings, highlighting gaps in care and the need for greater action.

Fix cardiorenalmetabolic care gaps: define ownership, task-shift screening, boost uACR testing, and tackle obesity-driven equity barriers.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Orbital rhabdomyosarcoma survival held steady despite less-intensive chemo and radiation, according to 25-year data.